Skip to main navigation
Skip to search
Skip to main content
Experts@Minnesota Home
Search content at Experts@Minnesota
Home
Profiles
Research units
University Assets
Projects and Grants
Research output
Datasets
Press/Media
Activities
Fellowships, Honors, and Prizes
Impacts
Convalescent Plasma
Ruchika Goel
,
Claudia S. Cohn
, Aaron A.R. Tobian
Laboratory Medicine and Pathology
Research output
:
Chapter in Book/Report/Conference proceeding
›
Chapter
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Convalescent Plasma'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Convalescent Plasma
100%
Standard of Care
28%
COVID-19
28%
Biotherapy
28%
Convalescent Plasma Therapy
28%
Trial Data
28%
Disease Progression
14%
Immunosuppression
14%
Disease Risk
14%
Inpatient Setting
14%
Randomized Trial
14%
Clinical Practice Guidelines
14%
High Risk
14%
Pre-exposure Prophylaxis (PrEP)
14%
Mechanism of Action
14%
Viral Load
14%
Transfusion
14%
Antibody Therapy
14%
Neutralizing Titer
14%
Outpatient Setting
14%
Antibody Titer
14%
Polyclonal Antibody
14%
Donor Center
14%
Serious Adverse Effects
14%
Blood Center
14%
Non-neutralizing
14%
Hospital Center
14%
Safety Metrics
14%
SARS-CoV-2 Antibodies
14%
HIV-infected Patients
14%
Expanded Access
14%
Well Tolerated
14%
Symptom Onset
14%
Putative Mechanisms
14%
Rapid Deployment
14%
Medicine and Dentistry
Convalescence
100%
COVID-19
28%
Biological Therapy
28%
Plasma Transfusion
28%
Disease Exacerbation
14%
Outpatient
14%
Immunosuppressive Treatment
14%
Epidemic
14%
Adverse Event
14%
Compassionate Use
14%
Severe Acute Respiratory Syndrome Coronavirus 2
14%
Polyclonal Antibody
14%
Post-Exposure Prophylaxis
14%
Antibody Therapy
14%
Diseases
14%
Pandemic
14%
Pharmacology, Toxicology and Pharmaceutical Science
Convalescence
100%
Disease Exacerbation
14%
Adverse Event
14%
Pandemic
14%
SARS Coronavirus
14%
Polyclonal Antibody
14%
Epidemic
14%
Diseases
14%
Immunology and Microbiology
Blood Plasma
100%
COVID-19
22%
Immunosuppression
11%
Viral Load
11%
Severe Acute Respiratory Syndrome Coronavirus 2
11%
Titer
11%
Polyclonal Antibody
11%
Antibody Titer
11%